The pharma executive working to end HIV in our lifetime

Mercier highlights the launch of Lenacapavir, a "twice-yearly injection" for HIV prevention with "99.9% efficacy," and notes the company is building out its oncology platform in breast cancer and lymphoma. The shift from daily pills to a biannual injection represents a massive quality-of-life improvement for patients, creating a strong competitive moat against competitors like GSK (whose injectable is every 2 months). The rapid voluntary licensing for developing nations mitigates global drug pricing/IP criticism (ESG risk), allowing Gilead to protect high-margin pricing in the US and EU while securing its status as the global standard of care. Long GILD as it solidifies its dominance in the HIV market through superior delivery mechanisms and diversifies revenue via its growing oncology pipeline. Regulatory hurdles in new oncology indications, patent expirations on legacy HIV drugs, or safety issues emerging with long-acting formulations.